Laddar populära aktier...
Den virtuella satellitsnätsoperatören Wyld Networks ("Wyld") har påbörjat leverans av produkter unde...
Redeye trims its forecasts for Q1 2024 slightly while retaining its Base Case and comments on the FT...
With the broadening of its Digital Cash technology to support secure Host-based Card Emulation (HCE)...
2024 förväntas bli ett övergångsår men de långsiktiga tillväxtutsikterna framstår som goda.
Cantargia today reported the preparations for the clinical trial of nadunolimab in leukaemia is goin...
Redeye comments on the news that Alzecure has announced a rights issue of up to SEK68m in total.
Redeye comments on Freemelt’s new order from Saab Dynamics.
Sivers has announced the resignation of CEO Anders Strom, who is leaving his position to pursue new ...
Smart Eye’s CEO Martin Krantz and CFO Mats Benjaminsson presented the background and purpose of the ...
IRLAB Therapeutics has confirmed the FDA’s alignment with its proposed Phase III programme for mesdo...
Inga större ordrar under Q1’24 och tuffa jämförelsetal Under H1’24 möter MilDef tuffa jämförelsetal.
Redeye gives its estimate changes in Smart Eye following the recent news flow in the company.
Adj. EBITDA of GBP 2m in line with pre-annoucement (ABGSCe 3m) We trim sales but raise '24e EBIT fro...
Redeye leaves a comment following the Magle Group’s announced public offer to acquire Amniotics earl...
Redeye endorses the outcome of IRLAB’s end of phase II meeting with the FDA, including the recently ...